Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Assessing treatment options for multiple myeloma and managing lenalidomide-refractory disease

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.05.19
Views: 341
Rating:

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Prof Xavier Leleu speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the types of topics that were presented on the second day of this meeting.

He explains what will be discussed in tomorrow's session, including a debate about the use of all available drugs to cure multiple myeloma versus the use of sequential treatment.

Prof Leleu also discusses the clinical management of lenalidomide-refractory disease, where subsequent lines of therapy could be affected.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

18.06.19

no rating
Cancer care in Latin America

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation